Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Chou, Wei Yang ^a   Soltani, A ^b   Sung, M ^b   Walters, J A E ^b   Wood Baker, R ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFECT; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SMOKING HABIT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 44949190506     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006897     Document Type: Review

References (16)

1. Dewar 2006 Dewar M, Whit Curry R. Chronic obstructive pulmonary disease: diagnostic considerations. American Family Physician 2006.;73:670-6.
2. Donaldson 2006 Donaldson GC, Wedzicha JA. COPD exacerbations 1: epidemiology. Thorax 2006;61:164-8.
3. GOLD 2006 GOLD. Global Strategy for Diagnosis, Management and Prevention of COPD - Updated 2006. http://www.goldcopd.org (accessed 18 August 2007).
4. Higgins 2003 Higgins JPT, Thompson SG, Deeks JD, Altman G. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
5. Hogg 2001 Hogg JC. Chronic obstructive pulmonary disease: an overview of pathology and pathogenesis. Novartis Foundation Symposium 2001;234:4-19.
6. Monso 1995 Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, Ausina V. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. American Journal of Respiratory and Critical Care Medicine 1995;152(4 Pt 1):1316-20.
7. Murray 1996 Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press, 1996.
8. Pauwels 2001 Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 2001;163:1256-76.
9. Pela 1998 Pela R, Marchesani F, Agostinelli C, Staccioli D, Cecarini L, Bassotti C, Sanguinetti CM. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Archives of Chest Disease 1998;53(3):262-7.
10. Pride 2002 Pride NB, Soriano JB. Chronic obstructive pulmonary disease in the United Kingdom: trends in mortality, morbidity and smoking. Current Opinion in Pulmonary Medicine 2002;8:95-101.
11. Rennard 2004 Rennard SI, Farmer SG. Exacerbations and progression of disease in asthma and chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2004;1(2):88-92.
12. Rodriguez-Roisin2000 Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(5 Suppl 2):398S-401S.
13. Seemungal 1998 Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1998;157:1418-22.
14. Seemungal 2000 Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2000;161(5):1608-13.
15. Sethi 2002 Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. The New England Journal of Medicine 2002;347(7):465-71.
16. Wood-Baker 2005 Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JAE. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 1.Art. No.: CD001288. DOI: 10.1002/14651858.CD001288.pub2.[MEDLINE: CD001288].